# An Exploratory Study of ADR-001 in Patients with Severe Pneumonia Caused by SARS-CoV-2 Infection

> **NCT04522986** · PHASE1 · COMPLETED · sponsor: **Rohto Pharmaceutical Co., Ltd.** · enrollment: 6 (actual)

## Conditions studied

- Severe Acute Respiratory Syndrome Coronavirus 2

## Interventions

- **BIOLOGICAL:** Mesenchymal stem cell

## Key facts

- **NCT ID:** NCT04522986
- **Lead sponsor:** Rohto Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-08-21
- **Primary completion:** 2021-02-02
- **Final completion:** 2021-02-02
- **Target enrollment:** 6 (ACTUAL)
- **Last updated:** 2024-12-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04522986

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04522986, "An Exploratory Study of ADR-001 in Patients with Severe Pneumonia Caused by SARS-CoV-2 Infection". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04522986. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*